



Yale Pulmonary Critical Care and Sleep Medicine Grand Rounds

YaleCME
CONTINUING MEDICAL EDUCATION

Presented by

Yale School of Medicine, Department of Internal Medicine, Section of Pulmonary, Critical Care and Sleep Medicine

Group III Pulmonary Hypertension: Longstanding Questions and New Perspectives



Hannah Oakland, MD

Fellow of Pulmonary and Critical Care Medicine
Yale School of Medicine

Wednesday, October 7, 2020 @ 3-4 pm EDT

Moderator: Phillip Joseph, MD

REMOTE ATTENDANCE ONLY – NO LOCAL AUDIENCE

PC, Mac, Linux, iOS or Android: <https://zoom.us/j/94544698749>

Telephone: Dial: +1 203 432-9666 or (+1 888 788-0099 or +1 877 853-5247 US Toll-free); Meeting ID: 945 4469 8749

CME credit for live event only.

There is no corporate support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut.

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

Attending physicians, house staff/fellows, medical students, nurses, physician assistants.

NEEDS ASSESSMENT

Pulmonary hypertension in chronic lung disease carries an extremely poor prognosis and is highly prevalent. Prior recommendations advised against the treatment of pulmonary hypertension in chronic lung disease with vasodilators and instead focused on management of the underlying lung disease and hypoxemia. However, recent evidence has called this into question, and the soon-to-be-published INCREASE trial may substantially modify this recommendation. This presentation will aim to discuss the controversy of the treatment of Group III pulmonary hypertension in order to guide the Section's clinical practice in this rapidly evolving and commonly-encountered clinical scenario.

LEARNING OBJECTIVES

At the conclusion of this talk, individuals will:

1. Define Group III Pulmonary Hypertension and describe its pathophysiology, prevalence and prognosis.

2. Review the extensive literature addressing the controversies of treatment of this disease.
3. Discuss upcoming evidence for the use of inhaled vasodilators in Group III Pulmonary Hypertension.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Richard Matthay, MD, Course Director – No conflicts of interest

Hannah Oakland, MD – No conflicts of interest

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.